Best Clean Energy Stocks To Buy Right Now

tags:EHTH,CHUY,IBB,MOSY, &l;p&g;&l;img class=&q;dam-image bloomberg size-large wp-image-41903517&q; src=&q;https://specials-images.forbesimg.com/dam/imageserve/41903517/960x0.jpg?fit=scale&q; data-height=&q;1390&q; data-width=&q;960&q;&g; A rainbow arcs over wind turbines at a wind farm in Scotland. Mike Wilkinson/Bloomberg

As the amount of renewable energy in global electricity networks continues to surge, a new question arises &a;ndash; when will renewables become the dominant source of energy?

A new report, the &l;a href=&q;https://www.lr.org/techradar&q; target=&q;_blank&q;&g;Lloyd&a;rsquo;s Register 2018 Technology Radar&l;/a&g;, examines this issue and also looks at which technologies are likely to have the biggest impact in different countries and what are the key drivers and barriers to success.

A survey of 800 key industry figures found that China would be the first country to achieve grid parity, in 2022, followed by Spain and the United Arab Emirates two years later in 2024. This is the same year that Germany and the UK are expected to see grid parity for wind power, followed a year later by Denmark and the USA. The International Renewable Energy Agency (IRENA) &l;a href=&q;http://www.irena.org/newsroom/pressreleases/2018/Jan/Onshore-Wind-Power-Now-as-Affordable-as-Any-Other-Source&q; target=&q;_blank&q;&g;said recently&l;/a&g; that clean energy sources will be cheaper than fossil fuels by 2020.

Best Clean Energy Stocks To Buy Right Now: eHealth Inc.(EHTH)

Advisors' Opinion:

• [By Lisa Levin]

  Shares of eHealth, Inc. (NASDAQ: EHTH) got a boost, shooting up 19 percent to $19.04 as the company posted upbeat Q1 results.

  SVB Financial Group (NASDAQ: SIVB) shares were also up, gaining 17 percent to $301.12 following strong quarterly results.

• [By Lisa Levin] Gainers Genprex, Inc. (NASDAQ: GNPX) jumped 46.7 percent to $16.1331. The low-float small-cap clinical stage gene therapy company saw its stock rally nearly 150 percent from Monday through Thursday. Formal news hasn't been announced this week that would support a triple-digit percentage rally (including more than 200 percent at one point on Thursday) but the quiet period following its initial public offering will expire on May 8. Celyad SA (NASDAQ: CYAD) shares gained 24.7 percent to $36.17. Celyad reported the publication of THINK study case report of CYAD-01 Induced Complete Remission in relapsed/refractory AML patient in haematologica. DMC Global Inc. (NASDAQ: BOOM) shares jumped 23.2 percent to $39.00 after the company reported upbeat Q1 results and issued upbeat Q2 guidance. eHealth, Inc. (NASDAQ: EHTH) gained 21.8 percent to $19.58 as the company posted upbeat Q1 results. Enova International, Inc. (NYSE: ENVA) climbed 20.4 percent to $27.20 following Q1 results. SVB Financial Group (NASDAQ: SIVB) shares jumped 18.2 percent to $304.135 following strong quarterly results. Knowles Corporation (NYSE: KN) gained 13.9 percent to $12.70 as the company reported Q1 results. Zymeworks Inc. (NYSE: ZYME) gained 13.8 percent to $17.36. Cocrystal Pharma, Inc. (NASDAQ: COCP) rose 11.8 percent to $2.336 after declining 25.09 percent on Thursday. ImmunoGen, Inc. (NASDAQ: IMGN) shares surged 11.7 percent to $11.75 after the company announced 'successful completion of interim analysis' for FORWARD I Phase 3 mirvetuximab soravtansine trial. Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX) gained 9.5 percent to $12.70. Expedia Group, Inc. (NASDAQ: EXPE) shares rose 8.5 percent to $115.3801 after the company reported stronger-than-expected earnings for its first quarter on Thursday. Sprint Corporation (NYSE: S) shares rose 8.3 percent to $6.50. The stock moved higher after a Reuters report suggested ongoing merger talks with T-M
• [By Lisa Levin]

  Shares of eHealth, Inc. (NASDAQ: EHTH) got a boost, shooting up 16 percent to $18.64 as the company posted upbeat Q1 results.

  Enova International, Inc. (NYSE: ENVA) shares were also up, gaining 25 percent to $28.35 following Q1 results.

Best Clean Energy Stocks To Buy Right Now: Chuy's Holdings, Inc.(CHUY)

Advisors' Opinion:

• [By Joseph Griffin]

  Chuy’s (NASDAQ:CHUY) had its price target hoisted by BMO Capital Markets from $27.00 to $28.00 in a report published on Wednesday, Marketbeat.com reports. The firm currently has a hold rating on the restaurant operator’s stock.

• [By Motley Fool Staff]

  Chuy's Holdings (NASDAQ:CHUY) Q1 2018 Earnings Conference CallMay. 8, 2018 4:30 p.m. ET

  Contents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks:

  Operator

• [By Dustin Parrett]

  Here are the top restaurant stocks we've found, with one-year price targets showing gains as high as 74%…

  Restaurant Stocks to Buy, No. 1: Chuy's Holdings Inc. (Nasdaq: CHUY)

  Chuy's Holdings Inc. (Nasdaq: CHUY) is a Texas-based chain of casual Tex-Mex restaurants.

Best Clean Energy Stocks To Buy Right Now: iShares Nasdaq Biotechnology Index Fund(IBB)

Advisors' Opinion:

• [By Jim Crumly]

  Biotech stocks had a big day, with the�iShares NASDAQ Biotechnology ETF (NASDAQ:IBB) jumping 2.8%. The broad technology sector slipped, and the�Technology Select Sector SPDR ETF (NYSEMKT:XLK)�lost 0.1%.

• [By Benzinga News Desk]

  After eking out a modest gain in the week ended April 27, the iShares NASDAQ Biotechnology Index (ETF) (NASDAQ: IBB) pulled back this week amid some not-so-encouraging earnings reports and negative regulatory decisions: Link

• [By ]

  October was not kind to the biggest names in biotech. While smaller, more speculative biotech names consolidated, the big kids fell off a cliff. The biotech slide accelerated midway through the month, with both the large-cap iShares Nasdaq Biotechnology ETF (NASDAQ:IBB) and the smaller SPDR S&P Biotech ETF slipping more than 5%.

• [By ]

  The SPDR S&P Biotech ETF (NYSE:XBI) �� a good measure of small-cap biotech stocks �� gained almost 6% yesterday. Meanwhile, the large-cap iShares Nasdaq Biotechnology ETF (NASDAQ:IBB) jumped almost 4%. The biotech buying frenzy helped lift the Nasdaq Composite to a gain of almost 1% in Monday��s session.

• [By Brian Feroldi, Keith Speights, and Sean Williams]

  The iShares Nasdaq Biotechnology ETF (NASDAQ:IBB)�-- which is an exchange-traded fund that holds nearly 200 biotech stocks -- has drastically underperformed the S&P 500 over the last three years. That fact suggests that there are bargains to be found in the biotech space.

Best Clean Energy Stocks To Buy Right Now: MoSys, Inc.(MOSY)

Advisors' Opinion:

• [By Money Morning Staff Reports]

  That's why today we'll show you one of our expert recommendations along with the 10 top-performing penny stocks to watch this week…

  Penny Stocks Current Share Price
  (as of Feb. 20) Feb. 12-20 Gain
  (as of Feb. 20) POET Technologies Inc. (OTCMKTS: POETF) $0.4165 85.1% Finjan Holdings Inc. (Nasdaq: FNJN) $2.94 67.05% Intelsat SA (NYSE: I) $3.50 38.89% Genesis Healthcare Inc. (NYSE: GEN) $1.39 37.62% Paringa Resources Ltd. (OTCMKTS: PNGZF) $0.41 32.30% CytoDyn Inc. (OTCMKTS: CYDY) $0.76 31.03% Iconix Brand Group Inc. (Nasdaq: ICON) $1.65 30.95% AMERI Holdings Inc. (Nasdaq: AMRH) $2.49 29.69% Pangea Logistics Solutions Ltd. (Nasdaq: PANL) $2.87 26.99% MoSys Inc. (Nasdaq: MOSY) $1.47 25.68%

  FREE PROFIT ALERTS: Get real-time recommendations on the best penny stock opportunities the moment we release them. Just sign up here, it's completely free…

• [By Lisa Levin] Gainers MoSys, Inc. (NASDAQ: MOSY) shares rose 44.7 percent to $2.20 in pre-market trading after the company reported better-than-expected Q1 results and issued strong Q2 forecast. The Trade Desk, Inc. (NASDAQ: TTD) rose 23.2 percent to $65.01 in pre-market trading after the company reported upbeat results for its first quarter. The company also issued strong second-quarter and FY18 sales guidance. Immersion Corporation (NASDAQ: IMMR) rose 17 percent to $13.55 in pre-market trading after reporting upbeat Q1 results. Akcea Therapeutics, Inc. (NASDAQ: AKCA) rose 13.8 percent to $23.50 in pre-market trading after the company disclosed that the FDA Advisory Committee voted in favor of WAYLIVRA for the treatment of familial chylomicronemia syndrome. RXi Pharmaceuticals Corporation (NASDAQ: RXII) rose 9.4 percent to $2.45 in pre-market trading after the company disclosed a collaboration with Iovance Biotherapeutics. ViewRay, Inc. (NASDAQ: VRAY) rose 13.7 percent to $8.80 in pre-market trading after reporting upbeat quarterly earnings. ForeScout Technologies, Inc. (NASDAQ: FSCT) rose 5.6 percent to $32.00 in pre-market trading after falling 2.26 percent on Thursday. Net 1 UEPS Technologies, Inc. (NASDAQ: UEPS) shares rose 5.6 percent to $9.30 in pre-market trading after reporting Q3 results. Aflac Incorporated (NYSE: AFL) rose 4.7 percent to $47.50 in pre-market trading. Clean Energy Fuels Corp. (NASDAQ: CLNE) rose 4.2 percent to $2.24 in pre-market trading following Q1 earnings. Kratos Defense & Security Solutions, Inc. (NASDAQ: KTOS) shares rose 3.7 percent to $11.00 in pre-market trading after the company reported Q1 earnings.

  Find out what's going on in today's market and bring any questions you have to Benzinga's PreMarket Prep.

• [By Lisa Levin]

  MoSys, Inc. (NASDAQ: MOSY) shares were also up, gaining 27 percent to $1.9265 after the company reported better-than-expected Q1 results and issued strong Q2 forecast.

KBC Group NV Sells 142,313 Shares of Principal Financial Group Inc (PFG)

KBC Group NV lowered its position in shares of Principal Financial Group Inc (NYSE:PFG) by 41.4% in the 1st quarter, according to its most recent disclosure with the SEC. The fund owned 201,808 shares of the financial services provider’s stock after selling 142,313 shares during the period. KBC Group NV’s holdings in Principal Financial Group were worth $12,292,000 as of its most recent filing with the SEC.

Several other institutional investors have also recently added to or reduced their stakes in the company. New Mexico Educational Retirement Board grew its position in shares of Principal Financial Group by 3.6% during the fourth quarter. New Mexico Educational Retirement Board now owns 25,804 shares of the financial services provider’s stock worth $1,821,000 after acquiring an additional 900 shares during the last quarter. Goelzer Investment Management Inc. grew its position in shares of Principal Financial Group by 0.5% during the fourth quarter. Goelzer Investment Management Inc. now owns 184,495 shares of the financial services provider’s stock worth $13,018,000 after acquiring an additional 957 shares during the last quarter. Citizens Financial Group Inc RI grew its position in shares of Principal Financial Group by 0.7% during the fourth quarter. Citizens Financial Group Inc RI now owns 157,190 shares of the financial services provider’s stock worth $11,092,000 after acquiring an additional 1,020 shares during the last quarter. Everence Capital Management Inc. grew its position in shares of Principal Financial Group by 16.8% during the fourth quarter. Everence Capital Management Inc. now owns 7,591 shares of the financial services provider’s stock worth $536,000 after acquiring an additional 1,091 shares during the last quarter. Finally, Advisor Group Inc. grew its position in shares of Principal Financial Group by 2.6% during the fourth quarter. Advisor Group Inc. now owns 45,893 shares of the financial services provider’s stock worth $3,239,000 after acquiring an additional 1,155 shares during the last quarter. Institutional investors and hedge funds own 68.64% of the company’s stock.

Get Principal Financial Group alerts:

In related news, insider Luis E. Valdes sold 27,662 shares of the company’s stock in a transaction dated Monday, February 26th. The shares were sold at an average price of $64.02, for a total value of $1,770,921.24. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 1.50% of the company’s stock.

PFG stock opened at $58.57 on Friday. Principal Financial Group Inc has a fifty-two week low of $54.89 and a fifty-two week high of $75.58. The company has a debt-to-equity ratio of 0.26, a quick ratio of 0.10 and a current ratio of 0.10.

Principal Financial Group (NYSE:PFG) last posted its quarterly earnings data on Thursday, April 26th. The financial services provider reported $1.40 earnings per share for the quarter, topping the consensus estimate of $1.35 by $0.05. The business had revenue of $2.91 billion during the quarter, compared to the consensus estimate of $3.54 billion. Principal Financial Group had a net margin of 12.35% and a return on equity of 13.55%. During the same quarter in the prior year, the company posted $1.27 earnings per share. research analysts anticipate that Principal Financial Group Inc will post 5.22 EPS for the current fiscal year.

Principal Financial Group announced that its Board of Directors has authorized a share buyback plan on Monday, May 7th that allows the company to repurchase $300.00 million in shares. This repurchase authorization allows the financial services provider to repurchase up to 1.7% of its shares through open market purchases. Shares repurchase plans are generally a sign that the company’s management believes its shares are undervalued.

The business also recently disclosed a quarterly dividend, which will be paid on Friday, June 29th. Investors of record on Monday, June 4th will be issued a $0.52 dividend. The ex-dividend date is Friday, June 1st. This represents a $2.08 annualized dividend and a yield of 3.55%. This is an increase from Principal Financial Group’s previous quarterly dividend of $0.51.

Several equities analysts have recently commented on the stock. JPMorgan Chase & Co. upgraded shares of Principal Financial Group from an “underweight” rating to a “neutral” rating and set a $70.00 price target for the company in a research report on Monday, February 12th. Keefe, Bruyette & Woods restated a “hold” rating and set a $76.00 price target on shares of Principal Financial Group in a research report on Wednesday, January 31st. Barclays upgraded shares of Principal Financial Group from an “equal weight” rating to an “overweight” rating and set a $72.00 price target for the company in a research report on Monday, February 12th. Wells Fargo & Co set a $66.00 price target on shares of Principal Financial Group and gave the stock a “hold” rating in a research report on Wednesday. Finally, Morgan Stanley reduced their price objective on shares of Principal Financial Group from $77.00 to $74.00 and set an “equal weight” rating for the company in a report on Friday, April 27th. Two analysts have rated the stock with a sell rating, seven have issued a hold rating and three have given a buy rating to the stock. Principal Financial Group currently has an average rating of “Hold” and an average target price of $71.00.

Principal Financial Group Company Profile

Principal Financial Group, Inc provides retirement, asset management, and insurance products and services to businesses, individuals, and institutional clients worldwide. It operates through Retirement and Income Solutions, Principal Global Investors, Principal International, and U.S. Insurance Solutions segments.

Want to see what other hedge funds are holding PFG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Principal Financial Group Inc (NYSE:PFG).

Sunesis Pharmaceuticals (SNSS) Earning Somewhat Favorable Media Coverage, Report Shows

News articles about Sunesis Pharmaceuticals (NASDAQ:SNSS) have been trending somewhat positive on Thursday, according to Accern Sentiment. The research group identifies positive and negative media coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Sunesis Pharmaceuticals earned a news impact score of 0.14 on Accern’s scale. Accern also assigned news headlines about the biopharmaceutical company an impact score of 47.0694587803928 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near future.

Several research firms have weighed in on SNSS. Cantor Fitzgerald reiterated a “hold” rating and set a $4.00 price target on shares of Sunesis Pharmaceuticals in a research note on Thursday, March 8th. ValuEngine downgraded Sunesis Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Thursday, March 1st. Zacks Investment Research downgraded Sunesis Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Thursday, February 15th. Finally, Cowen reiterated a “hold” rating on shares of Sunesis Pharmaceuticals in a research note on Tuesday, May 8th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and four have assigned a buy rating to the stock. The company has an average rating of “Hold” and an average target price of $4.12.

Get Sunesis Pharmaceuticals alerts:

Sunesis Pharmaceuticals traded up $0.05, hitting $2.51, during trading hours on Thursday, Marketbeat Ratings reports. 202 shares of the stock traded hands, compared to its average volume of 79,787. The company has a market cap of $95.55 million, a PE ratio of -1.73 and a beta of 1.79. Sunesis Pharmaceuticals has a 1 year low of $1.82 and a 1 year high of $7.69.

Sunesis Pharmaceuticals (NASDAQ:SNSS) last posted its quarterly earnings results on Tuesday, May 8th. The biopharmaceutical company reported ($0.21) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.27) by $0.06. The firm had revenue of $0.24 million for the quarter. analysts expect that Sunesis Pharmaceuticals will post -0.97 EPS for the current fiscal year.

Sunesis Pharmaceuticals Company Profile

Sunesis Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of oncology therapeutics for the treatment of solid and hematologic cancers. Its lead program is vecabrutinib, a non-covalently binding inhibitor of Bruton's tyrosine kinase (BTK), which is in Phase 1b/2 clinical trial in B-cell malignancies.

BTC Capital Management Inc. Purchases 16,388 Shares of New Senior Investment Group (SNR)

BTC Capital Management Inc. boosted its position in New Senior Investment Group (NYSE:SNR) by 160.6% in the first quarter, HoldingsChannel reports. The firm owned 26,595 shares of the real estate investment trust’s stock after purchasing an additional 16,388 shares during the quarter. BTC Capital Management Inc.’s holdings in New Senior Investment Group were worth $217,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently modified their holdings of the business. Northern Trust Corp increased its holdings in New Senior Investment Group by 6.7% in the 1st quarter. Northern Trust Corp now owns 1,470,220 shares of the real estate investment trust’s stock worth $12,027,000 after purchasing an additional 91,777 shares in the last quarter. WESPAC Advisors LLC increased its holdings in New Senior Investment Group by 30.5% in the 1st quarter. WESPAC Advisors LLC now owns 108,535 shares of the real estate investment trust’s stock worth $888,000 after purchasing an additional 25,381 shares in the last quarter. Teachers Insurance & Annuity Association of America acquired a new position in New Senior Investment Group in the 1st quarter worth about $887,000. Thompson Siegel & Walmsley LLC increased its holdings in New Senior Investment Group by 45.3% in the 1st quarter. Thompson Siegel & Walmsley LLC now owns 77,150 shares of the real estate investment trust’s stock worth $631,000 after purchasing an additional 24,071 shares in the last quarter. Finally, Aperio Group LLC increased its holdings in New Senior Investment Group by 52.6% in the 1st quarter. Aperio Group LLC now owns 45,674 shares of the real estate investment trust’s stock worth $374,000 after purchasing an additional 15,749 shares in the last quarter. 68.94% of the stock is owned by institutional investors and hedge funds.

Get New Senior Investment Group alerts:

SNR has been the subject of a number of recent research reports. Zacks Investment Research raised New Senior Investment Group from a “hold” rating to a “buy” rating and set a $9.00 target price for the company in a report on Wednesday, March 21st. ValuEngine cut New Senior Investment Group from a “buy” rating to a “hold” rating in a report on Wednesday, February 7th. Finally, Stifel Nicolaus reaffirmed a “hold” rating on shares of New Senior Investment Group in a report on Monday. Two analysts have rated the stock with a sell rating and four have assigned a hold rating to the stock. The stock has an average rating of “Hold” and a consensus price target of $9.31.

Shares of SNR stock opened at $7.81 on Thursday. The stock has a market capitalization of $625.15 million, a PE ratio of 6.85 and a beta of 0.61. The company has a quick ratio of 2.73, a current ratio of 2.73 and a debt-to-equity ratio of 4.04. New Senior Investment Group has a 1-year low of $6.77 and a 1-year high of $10.57.

New Senior Investment Group (NYSE:SNR) last issued its quarterly earnings results on Thursday, May 10th. The real estate investment trust reported ($0.16) earnings per share for the quarter, missing the consensus estimate of $0.24 by ($0.40). The company had revenue of $99.22 million during the quarter, compared to analyst estimates of $98.69 million. New Senior Investment Group had a net margin of 2.02% and a return on equity of 1.75%. The company’s quarterly revenue was down 13.7% on a year-over-year basis. During the same period in the previous year, the company posted $0.30 EPS. research analysts predict that New Senior Investment Group will post 1.01 earnings per share for the current year.

About New Senior Investment Group

New Senior Investment Group (NYSE: SNR) is a publicly-traded real estate investment trust with a diversified portfolio of senior housing properties located across the United States. As of December 31, 2017, New Senior is one of the largest owners of senior housing properties, with 133 properties across 37 states.

Want to see what other hedge funds are holding SNR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for New Senior Investment Group (NYSE:SNR).

Fiat Chrysler Automobiles (FCAU) Shares Gap Up to $21.86

Fiat Chrysler Automobiles (NYSE:FCAU) shares gapped up prior to trading on Monday . The stock had previously closed at $21.16, but opened at $21.86. Fiat Chrysler Automobiles shares last traded at $22.34, with a volume of 2377765 shares changing hands.

FCAU has been the topic of a number of research reports. Zacks Investment Research lowered Fiat Chrysler Automobiles from a “buy” rating to a “hold” rating in a report on Thursday, January 25th. Vetr raised Fiat Chrysler Automobiles from a “hold” rating to a “buy” rating and set a $25.70 price objective on the stock in a report on Monday, January 29th. Morgan Stanley upped their price objective on Fiat Chrysler Automobiles from $18.00 to $26.00 and gave the company an “overweight” rating in a report on Monday, February 5th. ValuEngine lowered Fiat Chrysler Automobiles from a “strong-buy” rating to a “buy” rating in a report on Monday, February 5th. Finally, Instinet initiated coverage on Fiat Chrysler Automobiles in a report on Wednesday, March 21st. They issued a “neutral” rating and a $21.10 price objective on the stock. Nine research analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company. The stock currently has an average rating of “Buy” and a consensus price target of $20.79.

Get Fiat Chrysler Automobiles alerts:

The firm has a market capitalization of $42.61 billion, a PE ratio of 8.21, a price-to-earnings-growth ratio of 0.23 and a beta of 2.06. The company has a debt-to-equity ratio of 0.49, a current ratio of 0.80 and a quick ratio of 0.50.

Fiat Chrysler Automobiles (NYSE:FCAU) last released its earnings results on Thursday, April 26th. The company reported $0.66 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.69 by ($0.03). The company had revenue of $27.03 billion for the quarter, compared to analyst estimates of $27.74 billion. Fiat Chrysler Automobiles had a return on equity of 20.10% and a net margin of 3.52%. The business’s revenue for the quarter was down 2.5% compared to the same quarter last year. During the same period last year, the company posted $0.43 earnings per share. equities research analysts anticipate that Fiat Chrysler Automobiles will post 3.93 EPS for the current year.

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Macquarie Group Ltd. grew its holdings in shares of Fiat Chrysler Automobiles by 6.2% during the 4th quarter. Macquarie Group Ltd. now owns 39,300 shares of the company’s stock worth $701,000 after purchasing an additional 2,300 shares in the last quarter. Sei Investments Co. grew its holdings in shares of Fiat Chrysler Automobiles by 7.5% during the 1st quarter. Sei Investments Co. now owns 36,830 shares of the company’s stock worth $756,000 after purchasing an additional 2,560 shares in the last quarter. IFP Advisors Inc lifted its position in shares of Fiat Chrysler Automobiles by 43.6% during the 1st quarter. IFP Advisors Inc now owns 8,618 shares of the company’s stock worth $177,000 after buying an additional 2,616 shares during the last quarter. Greenleaf Trust lifted its position in shares of Fiat Chrysler Automobiles by 15.3% during the 4th quarter. Greenleaf Trust now owns 20,884 shares of the company’s stock worth $373,000 after buying an additional 2,774 shares during the last quarter. Finally, First Allied Advisory Services Inc. lifted its position in shares of Fiat Chrysler Automobiles by 6.3% during the 4th quarter. First Allied Advisory Services Inc. now owns 50,258 shares of the company’s stock worth $896,000 after buying an additional 2,976 shares during the last quarter. 25.63% of the stock is currently owned by institutional investors.

Fiat Chrysler Automobiles Company Profile

Fiat Chrysler Automobiles N.V., together with its subsidiaries, designs, engineers, manufactures, distributes, and sells vehicles, components, and production systems. The company operates through six segments: NAFTA, LATAM, APAC, EMEA, Maserati, and Components. It provides passenger cars, trucks, and light commercial vehicles under the Jeep, Ram, Dodge, Chrysler, Fiat, Fiat Professional, Alfa Romeo, and Abarth brands; and luxury vehicles under the Maserati brand, as well as related service parts and accessories, and service contracts under the Mopar brand.

G1 Therapeutics (GTHX) Reaches New 1-Year High and Low After Analyst Upgrade

G1 Therapeutics (NASDAQ:GTHX) shares hit a new 52-week high and low during mid-day trading on Friday after Needham & Company LLC raised their price target on the stock from $42.00 to $60.00. Needham & Company LLC currently has a buy rating on the stock. G1 Therapeutics traded as low as $52.76 and last traded at $51.49, with a volume of 3566 shares changing hands. The stock had previously closed at $50.94.

A number of other research analysts also recently issued reports on GTHX. BidaskClub raised G1 Therapeutics from a “hold” rating to a “buy” rating in a report on Tuesday, January 23rd. JPMorgan Chase increased their target price on G1 Therapeutics to $30.00 in a report on Monday, February 5th. Zacks Investment Research downgraded G1 Therapeutics from a “hold” rating to a “sell” rating in a report on Thursday, February 8th. BTIG Research reissued a “buy” rating and issued a $38.00 target price on shares of G1 Therapeutics in a report on Thursday, February 22nd. Finally, Cowen reissued a “buy” rating on shares of G1 Therapeutics in a report on Monday, March 5th. Two investment analysts have rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the stock. G1 Therapeutics has an average rating of “Buy” and a consensus price target of $41.80.

Get G1 Therapeutics alerts:

In other news, VP Jennifer K. Moses sold 750 shares of the firm’s stock in a transaction dated Thursday, April 5th. The stock was sold at an average price of $37.47, for a total value of $28,102.50. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Mark A. Velleca sold 7,500 shares of the firm’s stock in a transaction dated Tuesday, May 15th. The stock was sold at an average price of $46.28, for a total value of $347,100.00. The disclosure for this sale can be found here. In the last three months, insiders sold 21,026 shares of company stock worth $843,033. 15.92% of the stock is owned by corporate insiders.

Several hedge funds and other institutional investors have recently bought and sold shares of GTHX. Schwab Charles Investment Management Inc. bought a new position in shares of G1 Therapeutics in the third quarter worth about $364,000. California State Teachers Retirement System bought a new position in shares of G1 Therapeutics in the third quarter worth about $319,000. Alps Advisors Inc. raised its stake in shares of G1 Therapeutics by 13.1% in the fourth quarter. Alps Advisors Inc. now owns 31,409 shares of the company’s stock worth $623,000 after buying an additional 3,643 shares during the period. Hodges Capital Management Inc. bought a new position in shares of G1 Therapeutics in the fourth quarter worth about $292,000. Finally, Swiss National Bank bought a new position in shares of G1 Therapeutics in the fourth quarter worth about $286,000. 42.11% of the stock is currently owned by hedge funds and other institutional investors.

The company has a market capitalization of $1.61 billion and a P/E ratio of -14.26.

G1 Therapeutics (NASDAQ:GTHX) last released its earnings results on Thursday, May 3rd. The company reported ($0.70) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.63) by ($0.07). equities analysts forecast that G1 Therapeutics will post -2.66 EPS for the current year.

About G1 Therapeutics

G1 Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel small molecule therapeutics for the treatment of patients with cancer in the United States. It is developing trilaciclib, an intravenous cyclin-dependent kinases (CDK) 4/6 inhibitor that is in Phase 1b/2a clinical trials for patients with small cell lung cancer, as well as Phase 2 clinical trial for patients with first-/second-/third-line metastatic triple-negative breast cancer; G1T38, an oral CDK4/6 inhibitor that is Phase 1b/2a clinical trials for the treatment of breast cancer; and G1T48, an oral selective estrogen receptor degrader, which is in preclinical development.

India is freaking out about rising oil prices

A spike in oil prices has the world's third largest consumer of energy worried.

India is seeking assurances from Saudi Arabia, OPEC's biggest producer, that oil prices will remain "stable and moderate," its government said in a statement on Friday.

Energy minister Dharmendra Pradhan spoke with Saudi oil minister Khalid Al-Falih late on Thursday to "express his concern about rising prices and its negative impact on consumers and the Indian economy," it said.

World oil prices have spiked by nearly 20% in 2018, and are up more than 40% over the past 12 months. President Donald Trump's decision to pull out of the Iran nuclear deal -- leading to concerns about Iranian supplies -- and a collapse in Venezuelan production have accelerated the price rise in recent weeks.

Brent crude, the global benchmark, crossed $80 per barrel on Thursday, while US crude futures hit $71.60 per barrel early Friday, their highest level since 2014.

$80 is 'way above reasonable'

Oil markets were already getting tighter following nearly 18 months of a deal between OPEC and Russia to curb their output to mop up a supply glut.

"We're not saying oil should be $25 a barrel, it should be at a price that is reasonable," Sanjay Sudhir, joint secretary for international cooperation at India's energy ministry, told CNNMoney. "$80 is way above a reasonable price, this is not a market-driven price."

Al-Falih told his Indian counterpart that Saudi Arabia would work with other OPEC producers and Russia "to "ensure availability of adequate supplies to offset any potential shortfalls," the kingdom's official news agency said.

OPEC and Russia discuss next move

Saudi Arabia has been discussing how to respond to the recent market volatility with the United Arab Emirates, the current OPEC president, and they'll consult with Russia next week on the sidelines of a conference in St. Petersburg, the agency reported. OPEC producers are due to meet in June to review their production cuts.

India has long been a major buyer of Iranian oil, though it has diversified its supply over the past few years through deals with Russia and, more recently, Saudi Arabia. The kingdom's state oil giant, Saudi Aramco, signed a a $44 billion deal last month to build a "mega refinery" in India with a consortium of Indian oil companies.

Indian concerns about oil price rises are understandable. Low oil prices played a big role in making it the world's fastest growing major economy in the recent years.

Every $10 increase in the price of a barrel knocks 0.2% to 0.3% off India's growth rate, according to the country's latest economic survey.

And growth in energy demand will be faster in India over the next two decades than any other country in the world, OPEC said in its World Oil Outlook 2040 released in November.

That demand could be threatened if oil prices keep rising, however.

"[India's] consumption will struggle to continue at its current pace, should oil prices continue to rise," analysts at BMI Research wrote in a recent note.

-- Ivana Kottasova contributed to this report